ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nurandociguat

Also written as “BAY3283142”, “Nurandociguat (BAY3283142) old tablet - SD” and “Nurandociguat (BAY3283142) new tablet - SD”.

Its studies are mostly in Renal Insufficiency, Chronic · Coronary Artery Disease, led by Bayer.

Drug pageNurandociguat: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jul 22, 20249 company-led studies, 1 open or runningNext primary completion: May 7, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer91 open or runningphase 2since Jul 22, 2024Jul 28, 2022May 7, 2027phase 1 · NCT07431294

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2022First study: phase 1 study in Renal Insufficiency, ChronicFirst studyNCT05515432 · 45 enrolled · Germany
  2. Aug 5, 2022Phase 1 study in Renal Insufficiency, ChronicNCT05491642 · 56 enrolled · Bulgaria, Germany
  3. Mar 24, 2023Phase 1 study in Renal Insufficiency, ChronicNCT05800444 · 24 enrolled · Japan
  4. Feb 29, 2024Named nurandociguatINNProposed as its International Nonproprietary Name in WHO's List 130 · before, BAY3283142
  5. May 3, 20242 phase 1 studies in Renal Insufficiency, ChronicNCT06402721, NCT06428825
  6. Jun 24, 2024Phase 1 study in Renal Insufficiency, ChronicNCT06487845 · 24 enrolled · China
  7. Jul 22, 2024Phase 2 study in Renal Insufficiency, ChronicNCT06522997 · 1,222 enrolled · United States, Argentina, Belgium and more
  8. Feb 16, 2026Phase 1 study in Stable Coronary Artery DiseaseNCT07431294 · 36 planned · Bulgaria, Germany
  9. Jul 17, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07722585 · 16 enrolled · Germany

Ahead

  1. May 7, 2027Primary completion: phase 1 study in Stable Coronary Artery DiseaseNCT07431294

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07722585Renal Insufficiency, Chronic · Germany1CompletedOct 12, 202616
NCT07431294Stable Coronary Artery Disease · Bulgaria, Germany1Not yet recruitingMay 7, 202736
NCT06522997Renal Insufficiency, Chronic · United States, Argentina, Belgium and more2CompletedOct 24, 20251,222
NCT06487845Renal Insufficiency, Chronic · China1CompletedSep 19, 202424
NCT06428825Renal Insufficiency, Chronic · Germany1CompletedNov 21, 202575
NCT06402721Renal Insufficiency, Chronic · United States1CompletedFeb 24, 202524
NCT05800444Renal Insufficiency, Chronic · Japan1CompletedJul 19, 202324
NCT05491642Renal Insufficiency, Chronic · Bulgaria, Germany1CompletedJan 3, 202356
NCT05515432Renal Insufficiency, Chronic · Germany1CompletedMar 7, 202345

How it is read

Names in the registry

  • “BAY3283142”, 6 entries
  • “Nurandociguat (BAY3283142) old tablet - SD”, 1 entry
  • “Nurandociguat (BAY3283142) new tablet - SD”, 1 entry
  • “Nurandociguat (BAY3283142) old tablet”, 1 entry
  • “Nurandociguat (BAY3283142) new tablet”, 1 entry

Codes read as this program: BAY3283142.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.